Literature DB >> 11244256

Virologic and biochemical changes and prognosis after liver resection for hepatitis B virus-related hepatocellular carcinoma.

S Kubo1, K Hirohashi, H Tanaka, T Tsukamoto, T Shuto, I Higaki, S Takemura, T Yamamoto, S Nishiguchi, H Kinoshita.   

Abstract

BACKGROUND/AIMS: During the natural course of hepatitis B virus (HBV) infection, clearance of HB e antigen (HBeAg) and HB surface antigen (HBsAg) occurs with remission of liver disease. We investigated the effects of postoperative changes in virologic and biochemical parameters on the prognosis after liver resection for HBV-related hepatocellular carcinoma (HCC).
METHODS: We investigated the relationship between postoperative changes in virologic and biochemical parameters and the incidence of intrahepatic recurrence and the outcome during a 3-year period following surgery in 30 HCC patients with HBsAg.
RESULTS: The incidence of intrahepatic recurrence of HCC was significantly higher in patients with acute postoperative exacerbation of hepatitis (p = 0.0084), a sustained high serum concentration of HBV DNA (> or = 5.0 mEq/ml, p = 0.001), and sustained expression of HBsAg after surgery (p = 0.0421). A high serum concentration of HBV DNA was significantly associated with a shorter survival time (p = 0.0447) and the cause of death was recurrence of HCC.
CONCLUSION: Patients with acute postoperative exacerbation of hepatitis, sustained HBsAg expression, and sustained high serum concentrations of HBV DNA after surgery may require more intensive postoperative monitoring for HCC recurrence.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11244256     DOI: 10.1159/000050093

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  10 in total

Review 1.  Treatment strategies for hepatocellular carcinoma in cirrhosis.

Authors:  W Scott Helton; Adrian Di Bisceglie; Ravi Chari; Myron Schwartz; Jordi Bruix
Journal:  J Gastrointest Surg       Date:  2003 Mar-Apr       Impact factor: 3.452

2.  High hepatitis B viral load predicts recurrence of small hepatocellular carcinoma after curative resection.

Authors:  Li-Shuai Qu; Fei Jin; Xiao-Wu Huang; Xi-Zhong Shen
Journal:  J Gastrointest Surg       Date:  2010-04-27       Impact factor: 3.452

Review 3.  Adjuvant therapy after curative resection for hepatocellular carcinoma associated with hepatitis virus.

Authors:  Shoji Kubo; Shigekazu Takemura; Chikaharu Sakata; Yorihisa Urata; Takahiro Uenishi
Journal:  Liver Cancer       Date:  2013-01       Impact factor: 11.740

4.  Prognostic effects of causative virus in hepatocellular carcinoma according to the Japan integrated staging (JIS) score.

Authors:  Shoji Kubo; Hiromu Tanaka; Taichi Shuto; Shigekazu Takemura; Takatsugu Yamamoto; Takahiro Uenishi; Shogo Tanaka; Seikan Hai; Satoshi Yamamoto; Tsuyoshi Ichikawa; Shintaro Kodai; Kazuhiro Hirohashi
Journal:  J Gastroenterol       Date:  2005-10       Impact factor: 7.527

Review 5.  Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma.

Authors:  Shoji Kubo; Shigekazu Takemura; Shogo Tanaka; Hiroji Shinkawa; Takayoshi Nishioka; Akinori Nozawa; Masahiko Kinoshita; Genya Hamano; Tokuji Ito; Yorihisa Urata
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

6.  Postoperative adjuvant arterial chemoembolization improves the survival of hepatitis B virus-related hepatocellular carcinoma: a retrospective control study.

Authors:  F Li; Z Guo; Y Zhang; H Wang; X Zhang; T Si; H Yu; L Qi
Journal:  Ir J Med Sci       Date:  2014-06-28       Impact factor: 1.568

7.  The effect of antiviral therapy on patients with hepatitis B virus-related hepatocellular carcinoma after curative resection: a systematic review and meta-analysis.

Authors:  Xu-Xiao Chen; Jian-Wen Cheng; Ao Huang; Xin Zhang; Jian Wang; Jia Fan; Jian Zhou; Xin-Rong Yang
Journal:  Onco Targets Ther       Date:  2017-11-10       Impact factor: 4.147

8.  Clinical cure and liver fibrosis reversal after postoperative antiviral combination therapy in hepatitis B-associated non-cirrhotic hepatocellular carcinoma: A case report.

Authors:  Xue-Ping Yu; Qi Lin; Zhi-Peng Huang; Wei-Shan Chen; Ming-Hui Zheng; Yi-Juan Zheng; Ju-Lan Li; Zhi-Jun Su
Journal:  World J Clin Cases       Date:  2021-01-26       Impact factor: 1.337

9.  Postoperative hepatitis B virus reactivation in hepatitis B virus-related hepatocellular carcinoma patients with hepatitis B virus DNA levels <500 copies/mL.

Authors:  Zhi-Bo Xie; Xiao-Bo Wang; De-Liang Fu; Jian-Hong Zhong; Xia-Wei Yang; Le-Qun Li
Journal:  Onco Targets Ther       Date:  2016-07-25       Impact factor: 4.147

10.  Two Nomograms to Select Hepatocellular Carcinoma Patients with Macroscopic Vascular Invasion for Hepatic Resection.

Authors:  Yiquan Jiang; Hui Tang; Zixian Wang; Yuanjing Sun; Wei Meng; Guoying Wang; Hua Li; Shuhong Yi; Genshu Wang; Yang Yang; Guihua Chen
Journal:  J Cancer       Date:  2018-09-07       Impact factor: 4.207

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.